Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women

• Published in: Breast cancer targets and therapy Vol. 3; no. default; pp. 9 - 19
• Main Authors: Patil, Vinayak W, Singhai, Rajeev, Patil, Amit V, Gurav, Prakash D
• Format: Journal Article
• Language: English
• Published: New Zealand Taylor & Francis Ltd 01.01.2011; Dove Press; Dove Medical Press
• Subjects: Breast cancer; Epidermal growth factor; HER-2/neu; hormone receptors; Ki-67; Medical prognosis; Original Research; PgR; TN breast cancer; Ki-67; HER-2/neu; PgR; ER; hormone receptors; TN breast cancer
• ISSN: 1179-1314; 1179-1314
• DOI: 10.2147/BCTT.S17094

The aim of our study was to analyze triple-negative (TN) breast cancer, which is defined as being negative for the estrogen receptor (ER), the progesterone receptor (PgR), and the human epidermal growth factor receptor 2 (HER-2/neu) and which represents a subset of breast cancer with different biologic behavior. We investigated the clinicopathological characteristics and prognostic indicators of lymph node-negative TN breast cancer. Medical records were reviewed from patients with node-negative breast cancer who underwent curative surgery at Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India, from May 2007 to October 2010. Clinicopathological variables and clinical outcomes were evaluated. Among 683 patients included, 136 had TN breast cancer and 529 had non-TN breast cancer. TN breast cancer correlated with younger age (<35 years, P = 0.003) and a higher histopathologic and nuclear grade (P < 0.001). It also correlated with a molecular profile associated with biological aggressiveness: negative for Bcl-2 expression (P < 0.001), positive for the epidermal growth factor receptor (P = 0.003), and a high level of p53 (P < 0.001) and Ki-67 expression (P < 0.00). The relapse rates during the follow-up period (median 56.8 months) were 14.7% for TN breast cancer and 6.6% for non-TN breast cancer (P = 0.004). Relapse-free survival (RFS) was significantly shorter among patients with TN breast cancer compared with those with non-TN breast cancer: 3.5-year RFS rate 85.5% versus 94.2%, respectively; P = 0.001. On multivariate analysis, young age, close resection margin, and triple negativity were independent predictors of shorter RFS. TN breast cancer had a higher relapse rate and more aggressive clinicopathological characteristics than non-TN in node-negative breast cancer. Thus, TN breast cancer should be integrated into risk factor analysis for node-negative breast cancer.